Lv1
20 积分 2023-12-20 加入
Biomarkers for immunotherapy of hepatocellular carcinoma
21天前
已完结
Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC
26天前
已完结
Biomarkers for immunotherapy of hepatocellular carcinoma
29天前
已完结
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Apatinib as second-line or later therapy inpatients with advanced hepatocellular carcinoma(AHELP): a multicentre, double-blind,randomised, placebo-controlled, phase 3 trial
2个月前
已完结
AFP Model Predicts Outcomes After Liver Resection: A Multicenter Retrospective Cohort Study
3个月前
已完结
Sintilimab and lenvatinib plus hepatic arterial infusion chemotherapy and embolization as conversion therapy for uHCC: A phase 2 trial
3个月前
已完结
Enhancing post-TIPS hepatic encephalopathy risk stratification: a hybrid TabPFN model leveraging radiomics, deep transfer learning features, and MELD score
5个月前
已完结
Porustobart(HBM4003)plus Toripalimab as Second-Line Therapy in Patients with AdvancedHepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
6个月前
已完结
Nivolumab versus sorafenib in advanced hepatocellularcarcinoma(CheckMate 459): a randomised, multicentre,open-label, phase 3 trial
10个月前
已完结
皖公网安备34019202002308
